Silencing FAT10 inhibits metastasis of osteosarcoma

International Journal of Oncology

Volumn 49, Issue 2, 2016, Pages 666-674

  Ma, Chengbin ^a   Zhang, Zhiyu ^b   Cui, Yan ^c   Yuan, Hongmou ^b   Wang, Feng ^a  

^a Departments of Spine Surgery   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c Joint Surgery   (China)

Author keywords

Catenin; FAT10; HOXB9; Osteosarcoma

Indexed keywords

HLA F LOCUS ADJACENT TRANSCRIPT 10; HOMEOBOX B9; HOMEODOMAIN PROTEIN; NERVE CELL ADHESION MOLECULE; UBIQUITIN; UNCLASSIFIED DRUG; UVOMORULIN; HOXB9 PROTEIN, HUMAN; UBD PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOINFORMATICS; CANCER PATIENT; CANCER PROGNOSIS; CELL ASSAY; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MATRIGEL ASSAY; METASTASIS ASSAY; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSWELL ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ADULT; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; OSTEOSARCOMA; UBIQUITINS;

EID: 84978381294     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3549     Document Type: Article

References (30)

1. Schwab JH, Springfield DS, Raskin KA, Mankin HJ and Hornicek FJ: What's new in primary bone tumors. J Bone Joint Surg Am 94: 1913-1919, 2012.
2. Cho Y, Jung GH, Chung SH, Kim JY, Choi Y and Kim JD: Long-term survivals of stage IIb osteosarcoma: A 20-year experience in a single institution. Clin Orthop Surg 3: 48-54, 2011.
3. Lewis VO: What's new in musculoskeletal oncology. J Bone Joint Surg Am 91: 1546-1556, 2009.
4. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
5. Wada T, Isu K, Takeda N, Usui M, Ishii S and Yamawaki S: A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: Preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colonystimulating factor. Oncology 53: 221-227, 1996.
6. Dikic I, Wakatsuki S and Walters KJ: Ubiquitin-binding domains-from structures to functions. Nat Rev Mol Cell Biol 10: 659-671, 2009.
7. Raasi S, Schmidtke G and Groettrup M: The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem 276: 35334-35343, 2001.
8. Hipp MS, Kalveram B, Raasi S, Groettrup M and Schmidtke G: FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 25: 3483-3491, 2005.
9. Ren J, Wang Y, Gao Y, Mehta SB and Lee CG: FAT10 mediates the effect of TNF-in inducing chromosomal instability. J Cell Sci 124: 3665-3675, 2011.
10. Merbl Y, Refour P, Patel H, Springer M and Kirschner MW: Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell 152: 1160-1172, 2013.
11. Ji F, Jin X, Jiao CH, Xu QW, Wang ZW and Chen YL: FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. World J Gastroenterol 15: 2228-2233, 2009.
12. Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong Tan S, Kan A, Nuchprayoon I, Jin R, Lee KH, et al: Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 22: 2592-2603, 2003.
13. Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K and Groettrup M: Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27: 6068-6074, 2008.
14. Sun GH, Liu YD, Yu G, Li N, Sun X and Yang J: Increased FAT10 expression is related to poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 35: 5167-5171, 2014.
15. Yuan J, Tu Y, Mao X, He S, Wang L, Fu G, Zong J and Zhang Y: Increased expression of FAT10 is correlated with progression and prognosis of human glioma. Pathol Oncol Res 18: 833-839, 2012.
16. Yuan R, Wang K, Hu J, Yan C, Li M, Yu X, Liu X, Lei J, Guo W, Wu L, et al: Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying catenin degradation. Cancer Res 74: 5287-5300, 2014.
17. Abate-Shen C: Deregulated homeobox gene expression in cancer: Cause or consequence? Nat Rev Cancer 2: 777-785, 2002.
18. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladany M, Gerald WL and Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62, 2009.
19. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco M, Wijendran V, Shioda T, et al: HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 107: 1100-1105, 2010.
20. Wen M, Kwon Y, Wang Y, Mao JH and Wei G: Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget 6: 25226-25239, 2015.
21. Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, et al: Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 88: 98-111, 2008.
22. Gao Y, Theng SS, Zhuo J, Teo WB, Ren J and Lee CG: FAT10, an ubiquitin-like protein, confers malignant properties in nontumorigenic and tumorigenic cells. Carcinogenesis 35: 923-934, 2014.
23. Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y and Wu D: As an independent prognostic factor, FAT10 promotes hepatitis B virusrelated hepatocellular carcinoma progression via Akt/GSK3? pathway. Oncogene 33: 909-920, 2014.
24. Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, et al: Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol 28: 2732-2744, 2008.
25. Miki T, Yasuda SY and Kahn M: Wnt/catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 7: 836-846, 2011.
26. Lai TY, Su CC, Kuo WW, Yeh YL, Kuo WH, Tsai FJ, Tsai CH, Weng YJ, Huang CY and Chen LM: catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol Rep 26: 415-422, 2011.
27. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262-4266, 2000.
28. Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9: 15-21, 1999.
29. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792, 1997.
30. Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: betacatenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804, 1997.